S100B is released from astrocytes upon inflammatory activation or metabolic stress, causing pericyte dysfunction and endothelial tight junction disruption. Elevated serum S100B precedes measurable amyloid or tau pathology. Major advantage: S100B is already FDA-cleared/IVD-registered for traumatic brain injury, providing established clinical laboratory infrastructure and assay standardization. This dramatically reduces development costs and timeline for AD adaptation.
Curated pathway from expert analysis
flowchart TD A["Calcium influx in astrocytes"] B["S100B release from astrocyte end-feet"] C["Pericyte contraction and dysfunction"] D["Endothelial tight junction disruption"] E["Blood-brain barrier dysfunction"] F["Elevated serum S100B"] G["Cognitive decline onset"] H["Amyloid and tau pathology progression"] A -->|"triggers"| B B -->|"acts on"| C C -->|"promotes"| D D -->|"causes"| E E -->|"results in"| F B -->|"precedes"| H E -->|"leads to"| G G -->|"accelerates"| H style A fill:#4fc3f7,color:#0d0d1a style B fill:#4fc3f7,color:#0d0d1a style C fill:#ef5350,color:#0d0d1a style D fill:#ef5350,color:#0d0d1a style E fill:#ef5350,color:#0d0d1a style F fill:#ffd54f,color:#0d0d1a style G fill:#ef5350,color:#0d0d1a style H fill:#ef5350,color:#0d0d1a
No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for S100B yet. Search RCSB →
Median TPM across 13 brain regions for S100B (S100 Calcium Binding Protein B) from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for S100B (S100 Calcium Binding Protein B).
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If astrocytic S100B release at end-feet is calcium-dependent and early indicator of BBB dysfunction, then elevated plasma S100B will precede and predict BBB breakdown (measured by Qalb and DCE-MRI) in | In 2-year longitudinal study (n≥100), baseline plasma S100B in top quartile predicts subsequent Qalb elevation (OR>4) and DCE-MRI Ktrans reduction within 12-18 | — no observation — | pending | 0.73 |